Does Blue Cross Blue Shield of Minnesota Cover Novolog?

How BCBSMN Classifies Novolog on Its Formularies

Blue Cross Blue Shield of Minnesota places Novolog on the majority of its commercial, individual, and Medicare Advantage drug formularies. The exact tier depends on your plan's benefit design, but most members will find insulin aspart listed as either a Tier 2 preferred brand or a Tier 3 non-preferred brand product.

BCBSMN maintains separate formularies for its fully insured commercial plans, self-funded employer groups, individual marketplace (MNsure) plans, and Medicare Advantage (Blue Cross Medicare) products. Each formulary undergoes review by a Pharmacy and Therapeutics (P&T) committee at least twice per year. Insulin aspart has maintained consistent formulary inclusion across these reviews because it remains one of the most widely prescribed rapid-acting insulin analogs in the United States. According to IQVIA data cited by the American Diabetes Association (ADA), rapid-acting insulin analogs account for roughly 90% of all mealtime insulin prescriptions in the U.S. [1].

Your member ID card and the BCBSMN online portal (bluecrossmn.com) provide the most accurate way to confirm Novolog's tier on your specific plan. Select "Find a Drug" and enter "Novolog" or "insulin aspart" to see your formulary listing, quantity limits, and any step-therapy requirements.

What You Can Expect to Pay Out of Pocket

For most BCBSMN commercial plans, a Tier 2 Novolog copay falls between $30 and $50 per 30-day supply for a standard vial (10 mL, 100 units/mL). FlexPen and FlexTouch devices typically carry the same tier but may have higher copays because of the per-unit cost of prefilled devices.

Minnesota state law provides a meaningful safety net. The Alec Smith Insulin Affordability Act, signed in 2020 and expanded in 2023, caps out-of-pocket costs for most insulin products at $35 per 30-day prescription for state-regulated health plans [2]. This cap applies to BCBSMN's fully insured plans and MNsure marketplace products. Self-funded employer plans regulated under federal ERISA law are not automatically subject to the Minnesota cap, though many large employers have adopted similar limits voluntarily.

For Medicare Advantage members enrolled in Blue Cross Medicare plans, the Inflation Reduction Act provision that took effect January 1, 2025 caps all Part D insulin copays at $35 per month [3]. This federal cap applies regardless of formulary tier, making Novolog accessible at a predictable monthly cost for Medicare beneficiaries.

The wholesale acquisition cost (WAC) of Novolog is approximately $340 per 10 mL vial, though net prices after rebates are substantially lower. Novo Nordisk reported a 2024 net price roughly 60% below list for its U.S. insulin portfolio, according to the company's integrated annual report [4]. This gap between list price and net price explains why formulary tier placement and copay structure matter more to patients than the sticker price.

Prior Authorization and Step-Therapy Rules

BCBSMN does not typically require prior authorization for standard Novolog vials, FlexPen, or FlexTouch on commercial formularies. This is a notable advantage compared to some specialty medications where prior authorization adds days or weeks to pharmacy fulfillment.

Certain exceptions exist. If your plan has implemented a step-therapy protocol, you may need to trial a preferred insulin aspart product (such as a biosimilar) before BCBSMN approves Novolog at the preferred tier. Step therapy does not block access entirely. It routes you toward the plan's lowest-cost clinically equivalent option first.

For insulin pump supplies using Novolog cartridges (PenFill), some BCBSMN plans classify these under durable medical equipment (DME) benefits rather than pharmacy benefits. DME coverage follows different cost-sharing rules. Contact BCBSMN member services at the number on your card to confirm whether your pump-related insulin falls under pharmacy or DME.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, noted in a 2023 ADA policy statement: "No person with diabetes should ever face rationing decisions because of cost barriers to insulin therapy" [5]. The ADA's Standards of Care recommend that prescribers consider formulary-preferred options and biosimilars alongside patient preference to reduce financial burden [1].

Biosimilar Insulin Aspart: A Lower-Cost Alternative on BCBSMN Formularies

The FDA has approved biosimilar versions of insulin aspart that may offer cost advantages on BCBSMN plans. Insulin aspart-afrz (marketed by Eli Lilly as Insulin Lispro, though distinct from lispro) and other biosimilar rapid-acting insulins have entered the market since 2020 [6].

The most clinically significant biosimilar for Novolog is insulin aspart (Biocon/Viatris), which received FDA approval as an interchangeable biosimilar. Interchangeable designation means a pharmacist can substitute the biosimilar for Novolog at the pharmacy counter without requiring a new prescription from the physician [7].

BCBSMN has placed certain biosimilar insulins at Tier 1 (preferred generic/biosimilar) on select formularies, which typically carries copays of $10 to $25 per 30-day supply. If cost is a primary concern, ask your prescriber whether a biosimilar insulin aspart is appropriate. The ADA's 2024 Standards of Care state that biosimilar insulins demonstrate "comparable efficacy and safety" to their reference products in randomized controlled trials [1].

A head-to-head trial (INSTRIDE-3, N=560) comparing biosimilar insulin aspart to reference Novolog in adults with type 1 diabetes showed equivalent HbA1c reduction at 52 weeks (mean difference 0.01%, 95% CI -0.11 to 0.13), confirming therapeutic equivalence [8]. Hypoglycemia rates were also comparable between groups.

How to Check Your Specific BCBSMN Plan

Not all BCBSMN cards are equal. The insurer offers more than 40 distinct formulary configurations across its product lines. Here is the fastest way to confirm your Novolog coverage.

Step 1: Log in to bluecrossmn.com or the Blue Cross MN mobile app. Step 2: Manage to "Pharmacy" or "Find a Drug." Step 3: Search for "Novolog" or "insulin aspart." Step 4: Review the tier, quantity limits, and any noted restrictions. The system returns results specific to your enrolled plan.

If you do not have online access, call BCBSMN member services (number on the back of your card). Request the following information: formulary tier for Novolog (all forms), applicable copay or coinsurance, whether prior authorization or step therapy applies, and whether biosimilar insulin aspart carries a lower tier on your plan.

Employer-sponsored self-funded plans are the most variable. Your employer's benefits team or human resources department can provide the summary of benefits and coverage (SBC) document, which lists your prescription drug tier structure and any insulin-specific cost-sharing provisions.

What to Do if Novolog Is Denied or Non-Preferred

A non-preferred tier placement does not mean you cannot get Novolog. It means your out-of-pocket cost will be higher unless you obtain a formulary exception. BCBSMN allows both standard and expedited exception requests.

To file a formulary exception, your prescribing physician submits a letter of medical necessity explaining why Novolog (rather than a preferred alternative) is required for your care. Common clinical reasons include documented adverse reactions to biosimilar or alternative rapid-acting insulins, demonstrated superior glycemic control on Novolog versus alternatives, or insulin pump compatibility requirements.

BCBSMN must respond to standard exception requests within 72 hours and expedited requests (where delay could cause serious harm) within 24 hours under Minnesota Department of Commerce regulations [9]. If your exception is denied, you have the right to appeal. The appeals process includes an internal review by a physician not involved in the original decision, followed by an external independent review if the internal appeal is unsuccessful.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, stated in a 2023 review published in The Lancet Diabetes & Endocrinology: "Switching insulin formulations solely for formulary reasons without clinical monitoring can disrupt glycemic stability, and patients who are well-controlled on a specific product deserve clinical consideration before forced substitution" [10].

Novo Nordisk Patient Assistance and Copay Programs

Even with BCBSMN coverage, some members face high cost-sharing, particularly those in high-deductible health plans (HDHPs) who have not yet met their annual deductible. Novo Nordisk offers several programs that can reduce costs.

The Novo Nordisk Patient Assistance Program (PAP) provides free insulin to qualifying uninsured or underinsured patients with household income at or below 400% of the federal poverty level [4]. Eligible individuals receive up to a 90-day supply at no cost.

For commercially insured patients, the NovoCare copay savings card can reduce Novolog copays to as low as $25 per 30-day prescription. This card is not valid for patients enrolled in Medicare, Medicaid, or other federal healthcare programs due to federal anti-kickback statute restrictions.

The Novo Nordisk Immediate Supply program allows any patient (regardless of insurance status) to purchase up to three vials or two packs of FlexPen at a pharmacy for $35, providing a critical bridge during coverage transitions or prior authorization delays.

The ADA's cost-reduction resource page lists additional state and nonprofit assistance options for patients struggling with insulin costs [5].

How Novolog Compares Clinically to Other Rapid-Acting Insulins

Novolog, Humalog (insulin lispro), and Apidra (insulin glulisine) are the three branded rapid-acting insulin analogs available in the United States. All three share similar onset (10 to 20 minutes), peak (1 to 3 hours), and duration (3 to 5 hours) profiles according to their FDA-approved labeling [6].

A Cochrane systematic review of 45 randomized controlled trials (N=13,591) comparing rapid-acting insulin analogs found no clinically significant difference in HbA1c reduction, severe hypoglycemia rates, or quality-of-life measures among the three analogs [11]. The review concluded that choice between rapid-acting insulins should be guided by patient preference, device familiarity, and cost rather than efficacy differences.

For BCBSMN members, this clinical equivalence means that switching from Novolog to a formulary-preferred rapid-acting insulin (whether Humalog, a biosimilar, or Admelog) is medically reasonable in most cases. The exception is patients using insulin pumps where device compatibility with a specific insulin formulation may be a factor, or patients with documented allergic reactions to specific insulin excipients.

In the SWITCH-2 trial (N=721), insulin degludec/insulin aspart showed a 30% relative reduction in nocturnal confirmed hypoglycemia compared to insulin glargine/insulin aspart in type 2 diabetes, though this involved basal insulin differences rather than rapid-acting component differences [12]. This trial underscores that the basal-bolus regimen architecture often matters more than the specific rapid-acting analog chosen.

Minnesota-Specific Insulin Protections You Should Know

Minnesota has enacted some of the strongest insulin access protections in the country. The Alec Smith Insulin Affordability Act provides two distinct pathways for residents who need affordable insulin.

The urgent need provision allows any Minnesota resident to obtain a one-time 30-day emergency supply of insulin at a pharmacy for no more than $35, without insurance, by attesting to an urgent need [2]. The continuing need provision provides ongoing 12-month access to insulin at $50 or less per 90-day supply for individuals who meet income eligibility criteria (household income at or below 400% of the federal poverty level).

These provisions function as a backstop and apply regardless of whether BCBSMN or any other insurer covers the medication. Pharmacists dispense insulin under these provisions and manufacturers reimburse the pharmacy.

The Minnesota Department of Commerce also requires all state-regulated health plans to cover at least one insulin product in each therapeutic category (rapid-acting, short-acting, intermediate-acting, long-acting) without prior authorization [9]. BCBSMN complies with this mandate across its fully insured product lines.

For 2024, approximately 3.6 million Minnesotans had private health insurance coverage, with Blue Cross Blue Shield of Minnesota holding the largest market share among commercial insurers in the state at roughly 30% [13]. This market position means that BCBSMN's formulary decisions on insulin directly affect more Minnesota residents than any other single insurer's policies.